A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
Filters
Generative FDG-PET and MRI Model of Aging and Disease Progression in Alzheimer's Disease
2013
PLoS Computational Biology
Preserved Fulltext
Here, we provide and validate at a group level a generative anatomical model of glucose hypo-metabolism and atrophy progression in AD based on FDG-PET and sMRI data of 80 patients and 79 healthy controls ...
The model suggests greater and more consistent changes in FDG-PET compared to sMRI at earlier and the inversion of this pattern at more advanced AD stages. ...
Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). ...
doi:10.1371/journal.pcbi.1002987
pmid:23592957
pmcid:PMC3616972
fatcat:sulattubbzc2vmoxmds2ke7qam
Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings
2015
Brain
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
We assessed demographic associations with N + , and A/N biomarker group frequencies by age where A + was defined by amyloid PET and N + was defined in five different ways: (i) abnormal adjusted hippocampal ...
70s and declined thereafter; and3 (iii) the frequency of AÀN + (suspected non-Alzheimer's pathophysiology) and of A + N + increased monotonically beginning in the mid-50s and mid-60s, respectively. ...
Both FDG PET and MRI are widely used measures of neurodegeneration (Jagust et al., 2009) where neurodegeneration is defined as progressive loss of neurons and their processes with a corresponding progressive ...
doi:10.1093/brain/awv283
pmid:26428666
pmcid:PMC4655341
fatcat:rezcndntszhqze2yf5ncsqcb4q
Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset
2019
Journal of Neurology
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Finally, FDG-PET showed a different prognostic value between earlier and later onset patients (p = 0.040) in time-to-progression allowing an estimate of the time free from disease. ...
The aim of this study is to assess the impact of age at onset on the prognostic value of Alzheimer's biomarkers in a large sample of patients with mild cognitive impairment (MCI). ...
Previous studies compared biomarker diagnostic value in EO and LO patients with Alzheimer's disease, finding highest diagnostic value for MRI in LO [16] , and for FDG-PET in EO patients with Alzheimer's ...
doi:10.1007/s00415-019-09441-7
pmid:31267207
fatcat:eqdykva2r5bvng5bhrdx76rao4
Relative contributions of biomarkers in Alzheimer's disease
2012
Annals of Epidemiology
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
, and were used to examine, at any given time, the joint contributions of hippocampal volume, whole brain volume, and brain glucose metabolism on clinical AD progression, using the Alzheimer's Disease ...
Effects of brain glucose metabolism differed in subgroups defined by baseline covariates (e.g., age), but no subgroup effects were observed for hippocampal volume and brain volume. ...
Acknowledgments Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ...
doi:10.1016/j.annepidem.2012.09.004
pmid:23102709
pmcid:PMC3510749
fatcat:jf5wusd7p5fsnbefqlewhcu64a
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
2013
Lancet Neurology
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
In 2010, we put forward a hypothetical model of the major biomarkers of Alzheimer's disease (AD). ...
The model was received with interest because we described the temporal evolution of AD biomarkers in relation to each other and to the onset and progression of clinical symptoms. ...
Acknowledgments We have received funding from the National Institutes of Health, grant AG11378. ...
doi:10.1016/s1474-4422(12)70291-0
pmid:23332364
pmcid:PMC3622225
fatcat:dfrw7udp65ayjmq65joch4sica
Grant Report on PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential Diagnosis
2019
Journal of Psychiatry and Brain Science
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
Studies utilizing FDG-PET have shown significant predictive ability in the prediction and progression of disease. ...
Further, we evaluated multimodal models that combine structural and FDG-PET imaging, in order to compare the predictive power of multimodal to unimodal models. ...
ACKNOWLEDGMENTS ADNI data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department ...
doi:10.20900/jpbs.20190017
pmid:31754634
pmcid:PMC6868780
fatcat:f65tcg424rcv7cbymqwa7pvkdi
A new data analysis approach for measuring longitudinal changes of metabolism in cognitively normal elderly adults
2017
Clinical Interventions in Aging
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Previously, we discussed several critical barriers in including [ 18 F] fluorodeoxyglucose positron emission tomography ([ 18 F]FDG-PET) imaging of preclinical Alzheimer's disease (AD) subjects. ...
In this study, we utilized a novel FDG-PET analysis, the regional FDG time correlation coefficient, rFTC, that can address and resolve these barriers and provide a more sensitive way of monitoring longitudinal ...
Age and gender were included as fixed effects in all models. ...
doi:10.2147/cia.s150859
pmid:29276381
pmcid:PMC5734228
fatcat:sgizuabhlnh3xiqynpcqeylxqu
Longitudinal Change of Biomarkers in Cognitive Decline
2011
Archives of Neurology
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
imaging and their relative associations with cognitive change at different stages in aging and Alzheimer disease (AD). ...
Setting: The 59 study sites for the Alzheimer's Disease Neuroimaging Initiative. ...
42 level in the CSF, FDG-PET regional metabolism, and MRI hippocampal volume. ...
doi:10.1001/archneurol.2011.123
pmid:21670386
pmcid:PMC5604752
fatcat:x4tqesjn3zcktoafme3wvw2x2e
Comparison of Regional Gray Matter Atrophy, White Matter Alteration, and Glucose Metabolism as a Predictor of the Conversion to Alzheimer's Disease in Mild Cognitive Impairment
2015
Journal of Korean medical science
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
We compared the predictive ability of the various neuroimaging tools and determined the most cost-effective, non-invasive Alzheimer's disease (AD) prediction model in mild cognitive impairment (MCI) individuals ...
Thirty-two MCI subjects were evaluated at baseline with [ 18 F]-fluorodeoxyglucose positron emission tomography (FDG-PET), MRI, diffusion tensor imaging (DTI), and neuropsychological tests, and then followed ...
DISCLOSURE The authors have no conflicts of interest to disclose.
AUTHOR CONTRIBUTION ...
doi:10.3346/jkms.2015.30.6.779
pmid:26028932
pmcid:PMC4444480
fatcat:i2hi4phpjndghp7opt6q3movfm
Glucose metabolism reflects local atrophy and tau pathology in symptomatic Alzheimers disease
[article]
2021
medRxiv
pre-print
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
age and disease severity (local model). ...
) underwent MRI and PET with FDG, amyloid-PET using [11C]-Pittsburgh Compound B, [18F]-Florbetapir, or [18F]-Florbetaben, and [18F]-Flortaucipir tau-PET within one year. ...
Amyloid-and FTP-PET are presented in SUVR units and FDG-PET and MRI volume in age-adjusted z-score, or W-score, units compared to cognitively normal controls. ...
doi:10.1101/2021.03.08.21252999
fatcat:jqj7a5abnjbnhifk2tt4ilwsca
Biomarker Modeling of Alzheimer's Disease
2013
Neuron
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many years to decades. ...
In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly ...
Figure labels are as in (A), except here the CSF tau, structural MRI, and FDG PET are grouped under the generic neurodegenerative label. ...
doi:10.1016/j.neuron.2013.12.003
pmid:24360540
pmcid:PMC3928967
fatcat:6la475cxe5fnvc5vc2x72nb73m
The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding
2015
Alzheimer's & Dementia
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Amyloid imaging and magnetic resonance imaging (MRI) summaries were assessed as predictors of disease progression. ...
INTRODUCTION-The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multi-site study designed to characterize the trajectories of biomarkers across the aging process. ...
ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer ...
doi:10.1016/j.jalz.2015.05.004
pmid:26194315
pmcid:PMC4510463
fatcat:d6u3dg3dqzasbeeeioud7jed3q
Quantitative multimodal multiparametric imaging in Alzheimer's disease
2016
Brain Informatics
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder, causing changes in memory, thinking, and other dysfunction of brain functions. ...
Fluorodeoxyglucose (FDG) PET and amyloid PET are applied in clinics and research departments. ...
in transgenic mouse models of Alzheimer's disease. ...
doi:10.1007/s40708-015-0028-9
pmid:27747597
pmcid:PMC4883163
fatcat:dj7x4hkj4vg4fp55ib3mscjtgu
Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression
2016
PLoS ONE
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
of Alzheimer's disease (AD) progression. ...
A logistic regression model to combine FDG parietal and posterior precuneus SUVR and Alzheimer's PLOS ONE | Disease Assessment Scale-Cognitive (ADAS-Cog) Total Mod was identified in predicating NC progression ...
ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following:
Author Contributions Conceived ...
doi:10.1371/journal.pone.0154406
pmid:27183116
pmcid:PMC4868310
fatcat:lxhzwih475hpta4ntmvhfrxf5a
Multimodal Discrimination between Normal Aging, Mild Cognitive Impairment and Alzheimer's Disease and Prediction of Cognitive Decline
2018
Diagnostics
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
a sample of normal aging subjects and those with MCI and AD from the Alzheimer's Disease Neuroimaging Initiative. ...
To achieve these aims, a series of multivariate stepwise logistic and linear regression models were generated. ...
Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense ...
doi:10.3390/diagnostics8010014
pmid:29415470
pmcid:PMC5871997
fatcat:xdh754wx7bb2lk4owed6tt3lha
« Previous
Showing results 1 — 15 out of 3,537 results